奥马珠单抗注射液联合复方甘草酸苷片治疗抗组胺药低反应慢性荨麻疹的效果

doi:10.3969/j.issn.1006-5725.2025.08.018

Abstract

Abstract:

Objective To investigate the effectiveness and safety of combining Omalizumab with compound glycyrrhetinic acid glycoside in the management of chronic urticaria that exhibits poor response to antihistamine therapy. Methods 92 patients with chronic urticaria who were treated with H1 antihistamines and still had symptoms from February 2022 to February 2024 in the hospital were selected as the study subjects. The study participants were randomly assigned to either the observation group， consisting of 46 cases， or the control group， also comprising 46 cases， using a random number table method. The control group received subcutaneous injection of omalizumab for treatment. The observation group was treated with oral compound glycyrrhizin tablets on the basis of the control group. After 24 weeks of treatment， compare the efficacy， adverse reactions， Urticaria Activity Score over 7 days （UAS7）， Dermatology Life Quality Index （DLQI）， Immunoglobulin （Ig） E， and High Sensitivity C-reactive protein （hs CRP） between the two groups， and record the recurrence rate. Results After treatment， the UAS7， DLQI， IgE and hs-CRP of both groups of patients decreased compared to before treatment， and the observation group demonstrated lower results compared to the control group （P < 0.05）. After treatment， the overall effectiveness rate in the observation group exceeded that of the control group（P < 0.05）， and the recurrence rate was lower than that of the control group （P < 0.05）. There was no statistically significant difference in the incidence of adverse reactions between the two groups of drugs （P > 0.05）. Conclusion The combination therapy of omalizumab and compound glycyrrhetinic acid glycoside in the treatment of chronic urticaria patients with low response to antihistamines helps reduce IgE expression， improve treatment effectiveness， lower recurrence rates， and does not increase adverse drug reactions.

Key words: chronic urticaria, omalizumab, compound glycyrrhetinic acid glycoside, antihistamines, therapeutic response

CLC Number:

Haixia SHI,Yuan GUO,Yanhua LI,Juping CHEN,Haochen YUAN,Yun. ZHANG. Effect of omalizumab injection combined with compound glycyrrhizin tablets on chronic urticaria with low response to antihistamines[J]. The Journal of Practical Medicine, 2025, 41(8): 1212-1216.

Figures/Tables 4

Tab.1

Comparison of general data"

组别	例数	性别/例		年龄/岁	体质量指数/（kg/m²）	病程/年	慢性荨麻疹初期分类/例
组别	例数	男	女	年龄/岁	体质量指数/（kg/m²）	病程/年	人工划痕性	胆碱能性	运动性
观察组	46	23	23	40.48 ± 14.69	23.59 ± 1.71	3.74 ± 1.12	24	11	11
对照组	46	27	19	44.52 ± 15.57	24.21 ± 1.39	3.91 ± 1.05	26	13	7
t/ $χ 2$ 值		0.701		1.281	1.908	0.751	1.136
P值		0.402		0.203	0.060	0.454	0.567

Tab.1

Tab.2

Tab.3

Tab.4

Efficacy evaluation"

组别	例数	完全应答	部分应答	无应答	有效率
观察组	46	25（54.35）	19（41.30）	2（4.35）	44（95.65）
对照组	46	20（43.48）	17（36.96）	9（19.57）	37（80.43）
$χ 2$ 值					5.059
P值					0.024

Tab.4

References 28

1	KOLKHIR P， MUNOZ M， ASERO R， et al. Autoimmune chronic spontaneous urticaria［J］. J Allergy Clin Immunol，2022，149（6）：1819-1831. doi:10.1016/j.jaci.2022.04.010 doi: 10.1016/j.jaci.2022.04.010
2	MAURER M， BERGER W， GIMENEZ-ARNAU A， et al. Remibrutinib， a novel BTK inhibitor， demonstrates promising efficacy and safety in chronic spontaneous urticaria［J］. J Allergy Clin Immunol，2022，150（6）：1498-1506. doi:10.1016/j.jaci.2022.08.027 doi: 10.1016/j.jaci.2022.08.027
3	刘薇. 地氯雷他定治疗过敏性疾病的临床研究进展［J］. 中国临床药理学与治疗学，2010，15 （7）：821-826.
4	CASALE T B， GIMENEZ-ARNAU A M， BERNSTEIN J A， et al. Omalizumab for Patients with Chronic Spontaneous Urticaria： A Narrative Review of Current Status［J］. Dermatol Ther （Heidelb），2023，13（11）：2573-2588. doi:10.1007/s13555-023-01040-9 doi: 10.1007/s13555-023-01040-9
5	KOLKHIR P， GIMENEZ-ARNAU A M， KULTHANAN K， et al. Urticaria［J］. Nat Rev Dis Primers，2022，8（1）：61. doi:10.1038/s41572-022-00389-z doi: 10.1038/s41572-022-00389-z
6	KAPLAN A， LEBWOHL M， GIMENEZ-ARNAU A M， et al. Chronic spontaneous urticaria： Focus on pathophysiology to unlock treatment advances［J］. Allergy，2023，78（2）：389-401. doi:10.1111/all.15603 doi: 10.1111/all.15603
7	LACAVA A F， FADUGBA O O. Cyclosporine for omalizumab-refractory chronic urticaria： A report of five cases［J］. Allergy Asthma Clin Immunol，2023，19（1）：78. doi:10.1186/s13223-023-00820-4 doi: 10.1186/s13223-023-00820-4
8	ZUBERBIER T， ABDUL L A， ABUZAKOUK M， et al. The international EAACI/GA（2）LEN/EuroGuiDerm/APAAACI guideline for the definition， classification， diagnosis， and management of urticaria［J］. Allergy，2022，77（3）：734-766.
9	CHEN S， CAO W， XIAO X， et al. A systematic review and meta-analysis of efficacy and safety of compound glycyrrhizin combined with second-generation non-sedated antihistamine for the treatment of chronic urticaria［J］. J Dermatolog Treat，2024，35（1）：2299597. doi:10.1080/09546634.2023.2299597 doi: 10.1080/09546634.2023.2299597
10	ORZAN O A， POPA L G， MIHAI M M， et al. Current and future approaches in management of chronic spontaneous urticaria using anti-IgE antibodies［J］. Medicina （Kaunas），2022，58（6）：816. doi:10.3390/medicina58060816 doi: 10.3390/medicina58060816
11	沈钰，蒋博宣，谢勇，等. 中药三黄苦参洗剂联合自制抗敏止痒乳膏治疗女性外阴慢性湿疹的效果观察［J］. 南通大学学报（医学版），2020，40（2）：188-190.
12	李思彤，王傲，白彦萍，等. 银屑病中滤泡性辅助性T细胞及IL-21对HaCaT细胞增殖及细胞周期的影响［J］. 实用医学杂志，2023，39（18）：2342-2348. doi:10.3969/j.issn.1006-5725.2023.18.010 doi: 10.3969/j.issn.1006-5725.2023.18.010
13	ZUBERBIER T， PETER J， STAUBACH P， et al. Potential Therapeutic Approaches for Chronic Urticaria： Beyond H1-Antihistamines and Biologics［J］. J Allergy Clin Immunol Pract，2023，11（8）：2265-2273. doi:10.1016/j.jaip.2023.06.027 doi: 10.1016/j.jaip.2023.06.027
14	NOCHAIWONG S， CHUAMANOCHAN M， RUENGORN C， et al. Impact of pharmacological treatments for chronic spontaneous urticaria with an inadequate response to H1-antihistamines on health-related quality of life： A systematic review and network meta-analysis［J］. J Allergy Clin Immunol Pract，2022，10（1）：297-308. doi:10.1016/j.jaip.2021.10.022 doi: 10.1016/j.jaip.2021.10.022
15	KEUMALA B W， MAHRI S， ALMIRA D. The Role of Adjuvant Therapy in the Management of Chronic Urticaria［J］. Actas Dermosifiliogr，2023，114（6）：T523-T530. doi:10.1016/j.ad.2023.02.015 doi: 10.1016/j.ad.2023.02.015
16	TURK M， ERTAS R， SAHINER U M， et al. In Chronic Spontaneous Urticaria， Complete Response to Antihistamine Treatment Is Linked to Low Disease Activity［J］. Int Arch Allergy Immunol，2023，184（5）：421-432. doi:10.1159/000528395 doi: 10.1159/000528395
17	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2022版）［J］. 中华皮肤科杂志，2022，55（12）：1041-1049.
18	岳淑珍，树叶，罗鸯鸯，等. 奥马珠单抗治疗儿童慢性荨麻疹的疗效和安全性回顾研究［J］. 中华皮肤科杂志，2024，57（4）：354-358.
19	JANG J H， YANG E M， LEE Y， et al. Increased serum free IgE levels in patients with chronic spontaneous urticaria （CSU）［J］. World Allergy Organ J，2022，15（2）：100629. doi:10.1016/j.waojou.2022.100629 doi: 10.1016/j.waojou.2022.100629
20	PATRUNO C， GUARNERI F， NETTIS E， et al. Safety of omalizumab in chronic urticaria during pregnancy： A real-life study［J］. Clin Exp Dermatol，2024，49（4）：344-347. doi:10.1093/ced/llad386 doi: 10.1093/ced/llad386
21	GIMENEZ-ARNAU A M， MANZANARES N， PODDER I. Recent updates in urticaria［J］. Med Clin （Barc），2023，161（10）：435-444. doi:10.1016/j.medcli.2023.06.026 doi: 10.1016/j.medcli.2023.06.026
22	MAURER M， CASALE T B， SAINI S S， et al. Dupilumab in patients with chronic spontaneous urticaria （LIBERTY-CSU CUPID）： Two randomized， double-blind， placebo-controlled， phase 3 trials［J］. J Allergy Clin Immunol，2024，154（1）：184-194. doi:10.1016/j.jaci.2024.01.028 doi: 10.1016/j.jaci.2024.01.028
23	BRAS R， COSTA C， LIMAO R， et al. Omalizumab in chronic spontaneous urticaria （CSU）： Real-life experience in dose/interval adjustments and treatment discontinuation［J］. J Allergy Clin Immunol Pract，2023，11（8）：2392-2402. doi:10.1016/j.jaip.2023.01.022 doi: 10.1016/j.jaip.2023.01.022
24	WEN Y， TANG Y， LI M， et al. Efficiency and safety of desloratadine in combination with compound glycyrrhizin in the treatment of chronic urticaria： A meta-analysis and systematic review of randomised controlled trials［J］. Pharm Biol，2021，59（1）：1276-1285. doi:10.1080/13880209.2021.1973039 doi: 10.1080/13880209.2021.1973039
25	WANG X， YI W， HE L， et al. Abnormalities in Gut Microbiota and Metabolism in Patients With Chronic Spontaneous Urticaria［J］. Front Immunol，2021，12（1）：691304. doi:10.3389/fimmu.2021.691304 doi: 10.3389/fimmu.2021.691304
26	KOLKHIR P， BONNEKOH H， METZ M， et al. Chronic Spontaneous Urticaria： A Review［J］. JAMA，2024，332（17）：1464-1477. doi:10.1001/jama.2024.15568 doi: 10.1001/jama.2024.15568
27	PEDERSEN N H， SORENSEN J A， GHAZANFAR M N， et al. Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria［J］. Int J Mol Sci，2023，24（14）：11328. doi:10.3390/ijms241411328 doi: 10.3390/ijms241411328
28	种树彬，刘春林. 复方甘草酸苷片联合盐酸西替利嗪治疗慢性荨麻疹患者的临床研究［J］. 中国临床药理学杂志，2022，38（24）：2954-2958.

组别	例数	UAS7		DLQI
组别	例数	治疗前	治疗后	治疗前	治疗后
观察组	46	27.02 ± 5.38	6.54 ± 3.62^#	19.12 ± 3.54	6.08 ± 2.33^#
对照组	46	25.16 ± 4.91	8.03 ± 2.18^#	18.36 ± 3.02	9.14 ± 3.27^#
t值		1.732	2.391	1.071	4.997
P值		0.087	0.019	0.281	0.001

组别	例数	IgE/（IU/mL）		hs-CRP/（mg/L）
组别	例数	治疗前	治疗后	治疗前	治疗后
观察组	46	112.95 ± 20.64	32.58 ± 6.07^#	16.09 ± 3.75	10.13 ± 2.24^#
对照组	46	116.21 ± 18.75	45.71 ± 6.25^#	15.37 ± 4.01	12.76 ± 2.51^#
t值		0.793	10.221	0.889	5.302
P值		0.430	0.001	0.376	0.001

[1]	Yan YOU,Hongjing CUI,Chengcheng PENG,Li JIANG,Qiyun ZHANG,Bingtao LI,Guoliang XU. The analysis of effect of serum containing Gegen Qinlian Decoction on regulating hypoxia-induced glucose metabolism in L02 Cells and related metabolic mechanisms [J]. The Journal of Practical Medicine, 2025, 41(7): 936-943.
[2]	Zhiwei GUAN,Qiong ZHAO,Jianli QIU,Yan XU,Qinwan HUANG,Hongyun ZHOU,Junqi ZHAO,Yinghui WU. Exploring the effect of modified Renshen Wumei Decoction on intestinal mucosal barrier in diarrhea rats based on TLR4/MyD88/pNF⁃κBp65 signaling pathway [J]. The Journal of Practical Medicine, 2025, 41(7): 944-952.
[3]	Hongyan BIAN,Shu ZHANG,Shanshan MENG,Ying WEI. Effect of pomegranate peel polyphenols on the malignant biological behavior of colon cancer cells by regulating the miR⁃138⁃5p/HIF⁃1α pathway [J]. The Journal of Practical Medicine, 2025, 41(5): 676-682.
[4]	Huixia YANG,Ning DING,Runqiu MA,Guizhong LI,Yinju HAO,Shengchao MA,Yideng JIANG,Zhigang. BAI. Role and mechanism of circular RNA mmu_circ_0000818 in dexamethasone⁃induced apoptosis of MC3T3⁃E1 cells [J]. The Journal of Practical Medicine, 2025, 41(4): 478-489.
[5]	Zhizhou XIAO,Ying HUANG,Huawei. BIAN. To investigate the effect of aloperine on bone metabolism in osteoporotic mice based on autophagy and apoptosis mediated by Wnt/β⁃catenin signaling pathway [J]. The Journal of Practical Medicine, 2025, 41(4): 500-508.
[6]	Wenyu ZHU,Hongwei ZHANG,Decai TANG,Fangyuan CHEN,Hua JIANG,Haiyan MIN,Jie. DING. Gypenosides LI down⁃regulates CPT1B through the pathway of lipid metabolism to inhibit the growth of colon cancer [J]. The Journal of Practical Medicine, 2025, 41(2): 162-169.
[7]	Huiling CAO,Jie ZHANG,Xiaofei ZHU,Shining QIAN,Yunfeng. CHEN. Study on the mechanism of tetramethylpyrazine pretreatment umbilical cord mesenchymal stem cell transplantation in the treatment of ischemic stroke [J]. The Journal of Practical Medicine, 2025, 41(2): 178-185.
[8]	Suzhen CHAO,Nian ZHOU,Xinyi SHI,Yili ZHOU,Junjie XIA,Bo LIU,Mingshi REN,Zihan. LI. Effect of mangiferin on differentiation of bone marrow mesenchymal stem cells induced by homocysteine [J]. The Journal of Practical Medicine, 2024, 40(23): 3284-3290.
[9]	Shengnan JIANG,Wenbing ZHI,Jing CHEN,Tingting SUN,Zongren XU,Shuai LIU,Hong ZHANG,Ye LI,Yang LIU. Sophora davidii Hance leaves total alkaloids Attenuate Lipopolysaccharide-induced inflammatory response in RAW264.7 cell by Inhibiting the MAPK/NF-κB signaling pathway [J]. The Journal of Practical Medicine, 2024, 40(20): 2835-2840.
[10]	Yangyang CHEN,Hongqi MA,Jing YANG,Zongyue WU,Ping. ZHU. Impact of Atractylodin on lung tissue damage in young asthma rats by regulating the CXCL12/CXCR4 signaling pathway [J]. The Journal of Practical Medicine, 2024, 40(19): 2672-2677.
[11]	Bin ZHANG,Wei HU,Rongzhen TAN,Panpan YANG,Jun HU,Zhong YUAN,Gongtao. JIANG. Effects of Yishen Huayu Xugu prescription combined with Dixumab on IL-6， β-CTX and bone mineral density in elderly patients operated for osteoporotic lumbar vertebral compression fractures [J]. The Journal of Practical Medicine, 2024, 40(19): 2766-2771.
[12]	Zhimin HUANG,Liangxi LU,Yini JIANG,Xiaoyu LIU,Zhiying ZHANG,Jinyu WU. Effects of Sanqi on Sortilin， TLRs and vascular calcification in rats with chronic renal failure [J]. The Journal of Practical Medicine, 2024, 40(6): 773-779.
[13]	Kanglin CAI,Jinkai ZHANG,Liangdi RAN,Dajun HU,Zhitao FENG,Huilian. HUANG. Research progress on antidepressant pharmacological effects and mechanisms of Bupleuri Radix⁃Paeoniae Radix Alba herb⁃pair [J]. The Journal of Practical Medicine, 2024, 40(4): 447-452.
[14]	Xiangzhi XIAO,Guanxiong CHEN,Zhiwen HU. The relationship between EGCG targeted regulation of Nrf2⁃Keap1 signaling pathway and neuroprotective effect in cerebral infarction [J]. The Journal of Practical Medicine, 2024, 40(3): 309-315.
[15]	Tian GU,Chunhong LIU,Fei ZHANG,Wei QIAN,Yanqiu ZHU,Mingliang CHU,Jiemin. LIU. The mechanism of emodin inhibiting YAP1 and FOXD1 in gastric cancer AGS cells and its related study [J]. The Journal of Practical Medicine, 2024, 40(1): 59-64.

Effect of omalizumab injection combined with compound glycyrrhizin tablets on chronic urticaria with low response to antihistamines

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 28

Related Articles 15

Recommended Articles

Metrics

Comments